Global Heart Failure Drugs Market Analysis

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Heart Failure Drugs Market Analysis

  • Healthcare
  • Upcoming Report
  • Jul 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Frequently Asked Questions

The market is segmented based on , By Type (ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blocker, Diuretics, Others), Application (Injection, Capsule, Tablets), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Users (Hospitals, Specialty Centres, Others) - Industry Trends and Forecast to 2030. .
The Global Heart Failure Drugs Market size was valued at USD 8010.62 USD Million in 2023.
The Global Heart Failure Drugs Market is projected to grow at a CAGR of 15.56% during the forecast period of 2024 to 2030.
The major players operating in the market include Amgen, AstraZeneca, Bayer, Novartis, Gilead Sciences, GlaxoSmithKline, Pfizer, Teva Pharmaceutical Industries, Cardurion Pharmaceuticals, Cardior Pharmaceuticals, Actelion Pharmaceuticals, Boehringer Ingelheim International, BristolMyers Squibb, CYTOKINETICS, and Eli Lilly and Company.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa.